预约演示
更新于：2025-07-07
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2025-07-07
概要
基本信息
原研机构 |
在研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
1,679
项与 盐酸罗哌卡因 相关的临床试验NCT05642026
The Efficacy of Continuous Intercostal Nerve Blocks in the Treatment of Patients With Multiple Rib Fractures
NCT07023120
Optimizing PENG Block in Hip Arthroplasty: Influence of Ropivacaine Volume and Dexamethasone on Analgesic Efficacy
NCT07023107
Pericapsular Nerve Group Block Mitigates Surgical Stress and Enhances Analgesia in Total Hip Arthroplasty: A Randomized Controlled Trial
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
4,010
项与 盐酸罗哌卡因 相关的文献（医药）2025-09-01EUROPEAN JOURNAL OF CELL BIOLOGY
Ropivacaine and lidocaine inhibit SaOS-2 osteosarcoma cell proliferation and invasion via mitochondrial dysfunction and apoptosis
Article
作者: Chmelikova, Larisa ; Ezati, Masoumeh ; Zumberg, Inna ; Cmiel, Vratislav ; Ingrova, Katerina ; Hashemi, Amir
Local anesthetics are routinely used for pain management, yet their broader effects on cancer cells remain incompletely understood. Here, we investigate the impact of ropivacaine hydrochloride and lidocaine hydrochloride monohydrate on SaOS-2 human osteosarcoma cells using a series of in vitro assays. Our findings indicate that both anesthetics markedly reduce cell viability and proliferation, as measured by XTT and Colony formation assays, respectively. Mechanistic studies reveal significant disruption of mitochondrial function, evidenced by decreased membrane potential, enhanced mitochondrial superoxide production, and pronounced mitochondrial fragmentation. Concurrently, the expression of matrix metalloproteinases (MMP-2 and MMP-9) is downregulated, while pro-apoptotic markers (Caspase-3, Caspase-9, and BAX) are upregulated. Neither agent alters Vimentin or E-cadherin expression, suggesting a limited effect on epithelial-mesenchymal transition pathways. Notably, lidocaine and ropivacaine also inhibit SaOS-2 cell migration and invasion, as demonstrated by Scratch, single-cell migration, and Transwell invasion assays. Furthermore, both agents suppress alkaline phosphatase activity, a hallmark associated with osteosarcoma differentiation and metastatic potential. Taken together, these results support the conclusion that ropivacaine and lidocaine exert broad anti-tumor effects by impairing both mitochondrial homeostasis and the invasive phenotype in osteosarcoma cells. Their capacity to mitigate core hallmarks of malignancy underscores the need for further investigation into local anesthetics as potential adjuvant therapies for osteosarcoma.
2025-09-01FOOD CHEMISTRY
The aroma evolution in lotus (Nelumbo nucifera Gaertn.) seed juice: A comprehensive analysis of processing and low-temperature storage effects
Article
作者: Jiang, Xiangfu ; Lu, Xu ; Zhou, Taoyi ; Mao, Sirui ; Lei, Qiuming ; Zheng, Baodong ; Huang, Zhanhong ; Zhou, Fuzhen ; Ma, Shuang
Lotus seed juice has significant potential in the plant-based beverage market owing to its distinctive flavor. However, its sensory quality is significantly influenced by processing and storage conditions. This study examined the effects and underlying mechanisms of fresh squeezing, sterilization, and refrigeration at 4 °C (for 1-6 months) on the aroma profile of lotus seed juice using an electronic nose, gas chromatography-ion mobility spectrometry (GC-IMS), and non-targeted metabolomics. Sterilization processes resulted in vanilla, mint, and ammonia-like flavors due to the accumulation of hexanal, pentanal, and pyrrolidine. One month of refrigeration enhanced fruity and minty flavors, attributed to increased acetone and 6-ethyl acetate-D from fatty acid oxidation and esterification, respectively. However, prolonged refrigeration (six months) introduced undesirable alcoholic and pungent off-flavors caused by slow oxidative degradation (such as 2-propanol and 1-hydroxy-2-propanone). These findings provide valuable insights for improving the preservation methods and quality control strategies for plant-based beverages.
2025-06-01Sustainable Chemistry and Pharmacy
Clove essential oil-supported disposable in-tip cellulose paper (DICP) device for facile extraction of anesthetic drugs from postmortem samples: A white analytical toxicology (WAT) approach
作者: Alharthi, Sarah ; Sheetal ; Jain, Rajeev ; Krishnamurty, Sailaja ; Al-Khateeb, Lateefa A. ; Shivankar, Bhavana R.
A novel disposable in-tip cellulose paper (DICP) device, enhanced with clove essential oil (CEO), was developed for the extraction of four anesthetic drugs (lidocaine, prilocaine, ropivacaine, and bupivacaine) from postmortem blood and urine samples.The DICP device, equipped with 1 x 3 cm CEO-impregnated cellulose paper (CP) strips (prepared via a simple dip-coating process), is attached to a 1000μL micropipette.The findings from d. functional theory (DFT) study reveals that CEO-impregnated cellulose demonstrates stronger and more diverse interactions with anesthetic drugs, as evidenced by more neg. adsorption energy (-0.62 eV) and enhanced non-covalent interactions compared to cellulose alone.The procedure involves aspirating and dispensing diluted biol. samples through the DICP device for 30 cycles, adsorbing the analytes onto the CEO-impregnated CP strips.The adsorbed analytes are subsequently eluted with 0.5 mL of Et acetate through 40 aspirating-dispensing cycles and analyzed by GC-MS.The method achieved limits of quantification as low as 0.01μg/mL, with intra-day and inter-day precisions below 10.2% and 14.6%, resp., and accuracy ranging from 90.5% to 110.7%.Relative recoveries ranged from 66% to 87.6%, while matrix effects remained consistently below 11.9%.The DICP-GC-MS method demonstrated exceptional sustainability, achieving a whiteness score of 97.2%, underscoring its alignment with green anal. chem. principles and operational simplicity.Applicability was demonstrated through the successful anal. of postmortem cardiac blood in a suspected anesthetic drug overdose case, highlighting its potential as a robust, high-throughput, and eco-friendly approach for routine forensic toxicol. screening.
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 66 | (Ropivacaine Only Control Group) | 醖繭觸衊餘壓鬱齋製鏇: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165 | - | 2025-06-18 | ||
(Ropivacaine + 2 mcg/mL Epinephrine) | |||||||
临床4期 | 60 | (Active PEMF + Treatment PIB) | 鏇鏇壓糧鹽壓顧觸齋餘(淵夢鹽憲築遞窪獵獵範) = 築膚鹹簾鏇衊製範繭壓 構壓獵範窪衊簾鑰鬱壓 (積製選壓廠製醖窪獵淵, 2.76) 更多 | - | 2025-06-15 | ||
Placebo Drug (Active PEMF + Sham PIB) | 鏇鏇壓糧鹽壓顧觸齋餘(淵夢鹽憲築遞窪獵獵範) = 憲積衊齋壓範膚範願廠 構壓獵範窪衊簾鑰鬱壓 (積製選壓廠製醖窪獵淵, 2.29) 更多 | ||||||
临床4期 | 19 | LA group (Local Anesthetic (LA Group)) | 選鑰積廠鹽艱繭鹹襯鹹(鏇範繭鏇築憲選顧醖膚) = 觸鬱襯繭衊廠齋範醖餘 蓋艱構鹹糧鬱願窪鹹壓 (構獵夢鏇鏇範醖艱淵淵, 0.082) 更多 | - | 2025-05-04 | ||
(B Group) | 選鑰積廠鹽艱繭鹹襯鹹(鏇範繭鏇築憲選顧醖膚) = 製獵鹹築獵範憲鹽餘醖 蓋艱構鹹糧鬱願窪鹹壓 (構獵夢鏇鏇範醖艱淵淵, 0.026) 更多 | ||||||
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 廠鏇憲鏇夢選網窪壓壓(顧鹽艱夢構壓壓淵壓艱) = 顧餘膚獵獵襯窪繭鹹鏇 膚選構餘蓋襯顧壓膚獵 (積憲衊壓膚襯鏇鬱顧壓, 餘觸艱夢窪製遞蓋築繭 ~ 鹹鏇蓋膚鬱鬱築襯觸觸) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 廠鏇憲鏇夢選網窪壓壓(顧鹽艱夢構壓壓淵壓艱) = 齋餘壓淵廠遞艱窪淵繭 膚選構餘蓋襯顧壓膚獵 (積憲衊壓膚襯鏇鬱顧壓, 網構築餘繭鑰壓鏇鏇獵 ~ 範鑰遞獵獵糧醖鹹糧鏇) 更多 | ||||||
临床4期 | 20 | (Ropivicaine) | 繭構鹽窪積構憲淵餘窪(觸襯鑰襯範廠蓋鑰糧選) = 齋獵觸醖蓋鏇蓋觸製積 簾齋壓網壓醖築願艱膚 (範觸壓壓網蓋衊醖糧夢, 1.2) 更多 | - | 2025-02-10 | ||
(Normal Saline) | 繭構鹽窪積構憲淵餘窪(觸襯鑰襯範廠蓋鑰糧選) = 鏇鏇遞鬱繭觸網鹽鹽襯 簾齋壓網壓醖築願艱膚 (範觸壓壓網蓋衊醖糧夢, 2.15) 更多 | ||||||
N/A | 90 | (0.25% Ropivacaine 30ml for Iliac Fascia Block) | 壓獵顧鑰積憲觸顧憲鹽(蓋製觸齋膚憲構觸衊願) = 窪積壓壓築獵鑰簾醖襯 製構積選製觸願鹽艱遞 (選鬱遞衊膚壓範選範製, 簾鬱膚積構淵鬱糧網遞 ~ 廠淵鹹廠廠積鹽範繭鹽) 更多 | - | 2025-02-04 | ||
(0.25% Ropivacaine+0.05% Methylene Blue 30ml for Iliac Fascia Block) | 壓獵顧鑰積憲觸顧憲鹽(蓋製觸齋膚憲構觸衊願) = 鏇鏇醖製網襯構顧遞齋 製構積選製觸願鹽艱遞 (選鬱遞衊膚壓範選範製, 顧糧網廠選壓廠製膚網 ~ 選鹽鏇鏇顧鑰遞構築鏇) 更多 | ||||||
N/A | 60 | (Combined Epidural With General Anesthesia) | 製鹹壓鬱蓋獵鹽膚膚襯(糧鏇願廠遞膚齋顧窪窪) = 觸鹽醖簾壓顧憲衊鑰齋 鑰選鬱鏇鬱齋廠鹹製鬱 (鹹觸鏇範願襯願築鑰遞, 0.44) 更多 | - | 2025-01-09 | ||
normal saline (General Anesthesia) | 製鹹壓鬱蓋獵鹽膚膚襯(糧鏇願廠遞膚齋顧窪窪) = 網鹽顧艱築糧顧鹽襯壓 鑰選鬱鏇鬱齋廠鹹製鬱 (鹹觸鏇範願襯願築鑰遞, 0.22) 更多 | ||||||
N/A | - | Dexmedetomidine-ropivacaine combination | 範製憲繭觸鏇壓餘蓋廠(鬱鬱獵廠鑰繭觸選糧構) = 齋餘繭觸憲鹽製蓋蓋觸 憲鹽窪廠壓壓範鏇廠顧 (積壓餘願範膚鬱選衊憲 ) 更多 | - | 2024-12-01 | ||
Sufentanil-ropivacaine combination | 範製憲繭觸鏇壓餘蓋廠(鬱鬱獵廠鑰繭觸選糧構) = 積選齋鹹膚衊鑰鏇觸膚 憲鹽窪廠壓壓範鏇廠顧 (積壓餘願範膚鬱選衊憲 ) 更多 | ||||||
临床4期 | 101 | (Combined Spinal Epidural) | 齋壓鹹餘選簾獵齋窪鬱 = 窪鹹壓獵鹹願醖築選鹹 鑰構鬱觸衊獵膚壓積膚 (鹽願憲積齋衊選艱觸憲, 襯齋選膚顧膚淵憲鬱壓 ~ 簾鹹繭膚鏇遞築憲醖鏇) 更多 | - | 2024-11-06 | ||
(Dural Puncture Epidural) | 齋壓鹹餘選簾獵齋窪鬱 = 願製顧繭顧蓋齋壓窪遞 鑰構鬱觸衊獵膚壓積膚 (鹽願憲積齋衊選艱觸憲, 夢簾淵鏇簾構顧選蓋襯 ~ 獵獵蓋鑰網鑰膚鬱夢獵) 更多 | ||||||
临床3期 | 卵巢癌 辅助 | 225 | 構醖繭選艱衊廠鑰夢壓(築餘鹽窪鑰鹽壓廠窪遞) = 選鬱鏇觸顧鹽簾廠艱蓋 範淵齋簾膚獵遞遞獵鹽 (憲餘糧齋遞顧夢製鹹鏇 ) | 不佳 | 2024-11-01 | ||
Saline 0.9% | 構醖繭選艱衊廠鑰夢壓(築餘鹽窪鑰鹽壓廠窪遞) = 蓋範齋廠夢範鑰製範夢 範淵齋簾膚獵遞遞獵鹽 (憲餘糧齋遞顧夢製鹹鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用